14 rue Ambroise Croizat, 77183 Croissy Beaubourg
France
Telephone +33 1 64621012
info@theradiag.com
http://www.theradiag.com
Product Categories
03 Diagnostics
03.02 Immunochemistry (Immunology)
03.02.16 Therapeutic drug monitoring
MEDICA 2017
Therapeutic drug monitoring
Monitoring the treatment of patients treated by anti-TNFα
Our platform
2 Products
03 Diagnostics
03.02 Immunochemistry (Immunology)
03.02.16 Therapeutic drug monitoring
03.02.16.01 Diagnostic agents / kits for determination of therapeutic drugs
MEDICA 2017
Diagnostic agents / kits for determination of therapeutic drugs
Monitoring the treatment of patients treated by anti-TNFα
Our platform
2 Products
ad: contact information
Company
Company details
Founded in 1986 by two former employees of Abbott France, Theradiag has been dedicated, at first, to distributing in vitro diagnostics, specifically for autoimmune diseases. The main stages of Theradiag’s development are the following:
2012
IPO of the company on NYSE Alternext on December 11th, 2012.
BMD becomes Theradiag.
2011
Patent filing for the monitoring of the treatment of autoimmune diseases by anti-TNFα, through multiple bio markers.
2010
Appointment of Michel Finance as Theradiag’s Chief Executive Officer.
2010
Launch by Theradiag in France, as part of an exclusive partnership, of two genetic and oncogenetic products supplied by the U.S. company Asuragen, expert in molecular biology and microARN technology.
2010
CE marking of the first Lisa-Tracker kit to monitor the treatment of autoimmune diseases by anti-TNFα.
2008
First financial support by OSEO Innovation, through a reimbursable fund of €550,000, for the development of a multi-parametric monitoring system for treatment of autoimmune diseases by anti-TNFα.
Initial growth of the Company in theranostics under the strategic industrial innovation plan, TRACKER, carried out in partnership with the French biotech company Neovacs. As part of OSEO Innovation’s support, Theradiag has already received some €1.5 million (in subsidies and reimbursable advances), notably to develop a universal solution to monitor the treatment of autoimmune diseases.
2006
Awarded “Innovative Company” for three years for its Innovation Mutual Funds (FCPI), by OSEO Innovation
2004
Commercial launch of FIDIS™, a line of autoimmune kits based on Luminex’s Multiplex technology and automated instruments.
2000
First fund-raising from venture capitalists to finance the Company’s growth.
2000
Expansion of its international distribution network by creating an export department and signing its first distribution partnerships.
1999
Signing of a development and sub-contracting agreement with the U.S. company Luminex to allow Theradiag to use Multiplex technology to develop an in house range of diagnostic materials and kits for autoimmune diseases diagnosis.
1992
Commercialization of the Company’s first in house products.
1990
Theradiag’s development into activities to complement research and development and production.
ad: contact information